12:00 AM
 | 
Oct 04, 1999
 |  BC Week In Review  |  Company News  |  Deals

Genzyme, ImmGenics deal

ImmGenics will use its SLAM immune cell selection technology to identify a high affinity monoclonal...

Read the full 51 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >